EP0944641B1 - Nicht-helikale supramolekulare nanosysteme - Google Patents
Nicht-helikale supramolekulare nanosysteme Download PDFInfo
- Publication number
- EP0944641B1 EP0944641B1 EP97952911A EP97952911A EP0944641B1 EP 0944641 B1 EP0944641 B1 EP 0944641B1 EP 97952911 A EP97952911 A EP 97952911A EP 97952911 A EP97952911 A EP 97952911A EP 0944641 B1 EP0944641 B1 EP 0944641B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- oligomer
- supramolecular
- supramolecular nanosystem
- pentopyranosyl
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B61/00—Other general methods
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
Definitions
- the present invention relates to a supramolecular nanosystem which has at least one im essential non-helical oligomer (oligomer A) and one or more, the same or different, essentially non-helical and non-pairing oligomers contains the same or different functional units (oligomer B), the oligomer A can specifically and non-covalently pair with oligomer B and oligomer B through its Monomers can be determined.
- oligomer A im essential non-helical oligomer
- oligomer B essentially non-helical and non-pairing oligomers
- the material properties caused or influenced by nanostructuring are mainly optical or chiroptical properties, e.g. B. in Kerr cells and at the LEP technique; electrical properties, e.g. B. in semiconductors or conductors by constitution of conduction tapes, defect electrons, color centers or areas with modulatable Tunneling currents; chemical, catalytic properties, such as B. in zeolites, metal cluster catalysis, Constitution of reaction spaces; as well as physical surface and Transport properties such as permeability, adhesion and compatibility with others Materials or sensitive biological systems (biocompatibility).
- optical or chiroptical properties e.g. B. in Kerr cells and at the LEP technique
- electrical properties e.g. B. in semiconductors or conductors by constitution of conduction tapes, defect electrons, color centers or areas with modulatable Tunneling currents
- chemical, catalytic properties such as B. in zeolites, metal cluster catalysis, Constitution of reaction spaces
- physical surface and Transport properties such as permeability, adhe
- the described nanomolecular properties are used in supramolecular chemistry specifically used to create new materials that can be used in the form of pairing systems can organize yourself.
- Pairing systems are supramolecular systems of non-covalent interaction that differ characterized by selectivity, stability and reversibility, and their properties preferred thermodynamically, d. H. e.g. influenced by temperature, pH and concentration become.
- DNA and RNA play a fundamental role as carriers of the hereditary system.
- Such pairing systems can e.g. B. because of their selective properties but also as "Molecular adhesive" for bringing together different metal clusters Cluster associations with potentially new properties can be used [Mirkin, C.A. et al., Nature, 1996, 382, 607-9; Alivisatos, A.P. et al., Nature, 1996, 382, 609-11).
- the Mating or hybridization properties of naturally occurring DNA have been described e.g. B.
- the object of the present invention was therefore to find a system which one or more of the described disadvantages avoided as far as possible.
- An object of the present invention is therefore a supramolecular nanosystem at least one essentially non-helical oligomer (oligomer A) and one or more, same or different, essentially non-helical and non-pairing Oligomers encoded with the same or different.
- oligomer A essentially non-helical oligomer
- Oligomer B oligomer B
- Non-covalent pairing in the sense of the present invention means an association of the Oligomer A with oligomer B via non-covalent interactions, such as Hydrogen bonds; Salt bridges, stacking, metaling, charge transfer complexes and hydrophobic interactions.
- Determinable in the sense of the present invention means that the. coded unit by the oligomer is addressed, i.e. is encoded.
- the code is determined by the one previously Sequence and type of monomers defined. This can be a specific one, for example Be nucleotide sequence.
- the type and order of the monomers of oligomer B determines the type and order of Monomers of oligomer A.
- these are each one of the other complementary nucleotides (see e.g. Figure 2).
- oligomer A can be combined with oligomer B mate with yourself in the form of a hairpin bow.
- This allows structural changes to be easily macroscopic under external conditions make inducible and determinable (see e.g. Figure 4).
- structural Changes in the molecular nanosystem according to the invention by changing the Equilibrium conditions such as Concentration of oligomer B, salt concentration, pH value, Pressure and / or temperature.
- Equilibrium conditions such as Concentration of oligomer B, salt concentration, pH value, Pressure and / or temperature.
- By hiring certain Equilibrium conditions can also be different areas for pairing or unpairing brought, so that reversible initially removed molecular residues in the immediate vicinity can be brought (so-called nano-transport).
- p-RNA pyranosyl-RNA
- the p-RNA as an example of a pentopyranosyl nucleic acid is a nucleic acid which instead of the ribofuranose of the RNA contains the ribopyranose as a sugar building block and therefore exclusively forms Watson-Crick- paired, antiparallel, reversibly "melting", quasi- linear and stable duplexes.
- homochiral p-RNA strands of opposite chirality which also pair in a controllable manner and are not strictly helical in the duplex formed.
- This specificity which is valuable for the construction of supramolecular units, is related to the relatively low flexibility of the ribopyranosephosphate backbone as well as the strong inclination of the base plane to the strand axis and the consequent tendency towards intercatenary base stacking in the resulting duplex and can be attributed to the participation of a 2 ', 4 '-Cis-disubstituted ribopyrano rings on the structure of the backbone. Because of the high selectivity and stability and the formation of strictly planar linear duplex strands, the pentopyranosyl nucleic acid and preferably the p-RNA is particularly preferred for the present invention.
- Pentopyranosyl nucleic acids can be, for example, according to Eschenmoser et al. (Helv Chim. Acta 1993, 76, 2161, Helv. Chim Acta 1995, 78, 1621, Angew Chem 1996, 108, 1619-1623) and are generally D- or L-configured.
- the supramolecular nanosystem serves as natural model the decoding of amino acids for protein synthesis by the respective base triplets as anticodon (see FIG. 1) present invention identical or different functional units to an oligomer one defined structure.
- a pentopyranosyl oligonucleotide which is modified at the 2 'and / or 4' end with free sulphydryl groups
- Monomaleimido-derivatized gold particles bound analogous to Alivisatos, A.P. et aL (1996), supra).
- oligomer B With the oligomer modified in this way (called oligomer B) one is used for this complementary oligomer A brought into contact so that the can form the supramolecular nanosystem according to the invention.
- the duplex strands formed are generally in a substantially planar-linear form, what is particularly advantageous.
- oligomer A is longer than oligomer B.
- One is particularly preferred Length of oligomer A from about 10 to about 500, preferably from about 10 to about 100 Monomer units.
- Oligomer B is generally about 4 to about 50, preferably about 4 to 25, in particular about 4 to about 15, especially about 4 to about 8 monomer units long.
- the pentopyranosyl part of the ptypyranosyl nucleic acid in the form of a thiophosphate, alkylated phosphate, phosphonare and / or Amides can be modified (see e.g. Uhlmann E. and Peyman A. (1990) Chemical Reviews, 90, 543-584, No. 4).
- the Coding of the oligomers of one of the canonical nucleobases adenine, guanine, cytosine, Thymine and / or uracil or isoguanine, isocytosine, 2,6-diaminopurine and / or Xanthine used.
- the complementary bases are in shape of isoguanine / isocytosine or 2,6-diaminopurine / xanthine pairs. Otherwise pairs in general adenosine with thymidine or uracil and guanosine with cytosine.
- the non-covalent pairing between oligomer A and oligomer B can take place via a chelating agent.
- a chelating agent for example, the nucleobases of a pentopyranosyl nucleic acid are replaced by the chelating agent.
- a metal ion for example Cu 2- or Ni 2- , complexation and thus specific pairing takes place between the two oligomers (see FIG. 3)
- a metal is preferably suitable as the encoded unit of oligomer B, preferably a metal cluster, in particular a precious metal, especially gold, silver and / or platinum. It Semiconductor connections are also suitable, e.g. Cadmium selenide and / or cadmium sulfide. A peptide which has a suitable linker is also suitable as the functional unit e.g. N-phthaloylaminoethyl uracil or N-phthaloyltryptamine, bound to the oligomer can be. Another functional unit is, for example, a redox center, i.e. on Electron donor or acceptor, e.g. a quinone or hydroquinone.
- Fluorescent markers e.g. Fluorophores and / or chromophores, e.g. Benzoquinones or Azobenzenes suitable.
- Other functional units can represent a chelating agent, which preferably of anthrocyans, polyoxycarboxylic acids, polyamines, Dimethylglyoxime, ethylenediaminetetraacetic acid and / or nitrilotriacetic acid, is derived, or also conductive oligomers, such as e.g. conjugated alkyne-alkene-aromatic compounds.
- oligonucleotides themselves can be automatically attached to an oligonucleotide synthesizer getting produced.
- the oligomer A with the oligomer B according to the Association linked i.e. be fixed.
- Chemical fixation is preferred, for example covalent networking, metathesis, rear coupling, Michael addition of Thiols and / or oxidative formation of disulfide bridges. It is particularly preferred if the supramolecular nanosystem according to the invention on a solid phase e.g. a so-called Wafer or carrier is pulled up.
- Ceramic, metal, in particular noble metal such as, for example, are suitable as carrier materials Gold, silver or platinum, glasses, plastics, crystalline materials or thin layers of Carrier especially of the materials mentioned, or (bio) molecular filaments such as cellulose or scaffold proteins.
- the carrier is generally covalent, quasi-covalent, supramolecular or physically and magnetically (Shepard, A.R. (1997) Nucleic Acids Res., 25, 3183-3185, no. 15), in an electric field or through a molecular sieve.
- the oligomer A either synthesized directly at the position of the carrier or at specific positions of the Carrier be "linked".
- Examples are conjugation and carrier methods via Periodic oxidation and reductive amination of the Schiff base, N-hydroxysuccinimide ester of preferably dicarboxylic acid linker, ethylenediamine phosphoamidate linker, mercapto, iodoacetyl or Maleinimido method and / or covalent or non-covalent biotin linker method.
- Another embodiment of the present invention is containing a library several different supramolecular nanosystems according to the invention. Particularly advantageous it is when the library is combinatorial.
- a combinatorial one Library is suitable, for example, for property screening, in that a statistical or (sub) library made according to combinatorial deconvolution techniques for complementary oligonucleotide pairs (see e.g. Wilson-Linguardo (1996) J. med. Chem., 39, 2720 to 2726).
- a combinatorial library is particularly suitable for catalyst searches.
- oligomer A is synthesized combinatorially and with several different oligomers B with different metal clusters as functional units paired.
- cluster library the diversity of which is directly involved that of oligomer A correlates.
- Sub-library routines are particularly suitable here, the one easy identification of the active species, e.g. Positional scanning or orthogonal Allow libraries.
- the cluster library can then be based on its homogeneous catalytic Properties, for example, in water for vinyl acetate monomer catalysis are examined.
- Pentopyranosyl nucleic acid contains a relatively high proportion of cytosine and guanosine because due to the higher binding enthalpy of this pair of nucleotides compared to adenosine or thymidine shorter oligonucleotides can be used, whereby the "Nucleotide load" of the supramolecular nanosystem according to the invention can be reduced can.
- the "nucleotide load" can be further reduced.
- the duplexes thus formed generally have an inclined, however, non-helical, repetitive structure that is specific depending on the choice of ligand Metal centers coordinate and metal-metal interactions along the duplex axis or desired defects. This allows controlled metal sequences manufacture a new nano-alloy set for the production of so-called "nano-wires" represent.
- the described supramolecular nanosystem according to the invention has a special one great stability and selectivity and is particularly suitable for self-organization. It also has controllable topicity and allows aggregation or self-organization influence each other particularly well dynamically.
- Areas of application are therefore in particular the production of electronic components such as z.
- Pyranosyl RNA was according to Eschenmoser et al. (supra) via a phosphoamidite synthesis manufactured. Gold clusters as in Mirkin C.A. et al. (1996), supra, described, bound. The complementary strands were in a buffer solution (1M NaCl, 10mM Tris-HCl, pH 7) paired at 0 ° C (see Fig. 2).
- the signals were assigned using a 1 H , 1 H - COZY spectrum.
- the signals were assigned using a 1 H , 13 C- COZY spectrum.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Description
- Fig. 1:
- Schematische Darstellung der natürliche Basenpaarung bei der Peptidsynthese
- Fig. 2:
- Schematische Darstellung eines erfindungsgemäßen supramolekularen Nanosystems mit den Nukleobasen Adenosin (A) und Thymidin (T) und verschiedenen funktionellen Einheiten als xl bis xl (codierende Einheiten) bezeichnet.
- Fig. 3:
- Schematische Darstellung eines Einzentrenchelatkomplexes über ein Pyrido[3,2-h]chinazolin-2(1)-on als Chelatbildner.
- Fig. 4:
- Schematische Darstellung einer Gleichgewichtsreaktion zwischen einer Haarnadelschleife und einem Duplex.
- Fig. 5:
- Ausschnitt einer Röntgenstrukturanalyse eines Nickelchelat-Ribopyranose-Pyrazolylpyridin-Komplexes
- Proben:
- LX626-1: MS-Nr.: 970523
- Aufgabenstellung:
- Massenspektrometrische Charakterisierung der Probe
- Massenspektrometer:
- TSQ 700 (Finnigan/MAT)
- Meßbedingungen:
- MS; Spritzenpumpe
- Ionisierung:
- Electrospray ionization (ESI)
- Ergebnisse:
- Das Massenspektrum zeigt eine Molmasse M = 2242.
C34H27 N3 O7 M= 589
Claims (23)
- Supramolekulares Nanosystem, das mindestenseine Pentopyranosyl-Nukleinsäure, wobei ein oder mehrere Nukleobasen auch durch einen Chelatbildner ersetzt sein können (Oligomer A) undein oder mehrere, gleiche oder verschiedene, und miteinander nichtpaarendePentopyranosyl-Nukleinsäuren, wobei ein oder mehrere Nukleobasen auch durch einen Chelatbildner ersetzt sein können, mit gleichen oder verschiedenen codierten Einheiten (Oligomer B)
enthält, wobei
das Oligomer A mit dem Oligomer B spezifisch nicht-kovalent paaren kann und das Oligomer B durch seine Monomere codiert ist. - Supramolekulares Nanosystem nach Anspruch 1, dadurch gekennzeichnet, daß das Oligomer A eine Haarnadelschleife ausbilden kann.
- Supramolekulares Nanosystem nach einem der Ansprüche 1 oder 2, dadurch gekennzeichnet, daß die Pentopyranosyl-Nukleinsäure eine Ribo-, Arabino-, Lyxo und/oder Xylo-pyranosyl-Nukleinsäure ist.
- Supramolekulares Nanosystem nach einem der Ansprüche 1 - 3, dadurch gekennzeichnet, daß der Pentopyranosyl-Teil der Pentopyranosyl-Nukleinsäure D- oder L-konfiguriert ist.
- Supramolekulares Nanosystem nach einem der Ansprüche 1 - 4, dadurch gekennzeichnet, daß das Oligomer A eine Länge von 10 bis 500 Monomereinheiten hat.
- Supramolekulares Nanosystem nach einem der Ansprüche 1 - 4, dadurch gekennzeichnet, daß das Oligomer B eine Länge von 4 bis 50 Monomereinheiten hat.
- Supramolekulares Nanosystem nach einem der Ansprüche 1 - 6, dadurch gekennzeichnet, daß der Pentopyranosyl-Teil der Pentopyranosyl-Nukleinsäure in Form eines Thiophosphates, alkylierten Phosphates, Phosphonates und/oder Amids vorhanden ist.
- Supramolekulares Nanosystem nach einem der Ansprüche -1 - 7, dadurch gekennzeichnet, daß die Nukleinsäure als Nucleobase Adenin, Guanin, Isoguanin, Cytosin, Isocytosin, Thymin, Uracil, 2,6-Diaminopurin und/oder Xanthin enthält.
- Supramolekulares Nanosystem nach einem der Ansprüche 1 - 8, dadurch gekennzeichnet, daß der Chelatbildner abgeleitet ist von Pyrazolylpyridin und/oder Pyridoquinazolin.
- Supramolekulares Nanosystem nach einem der Ansprüche 1 - 9, dadurch gekennzeichnet, daß die codierte Einheit ausgewählt ist aus einem Metall, einem Metallcluster, einer Halbleiterverbindung, einem Peptid, einem Redox-Zentrum, einem Fluoreszenzmarker, einem Chelatbildner und/oder einem leitenden Oligomer.
- Supramolekulares Nanosystem nach Anspruch 10, dadurch gekennzeichnet, daß das Metall ein Edelmetall ausgewählt aus der Gruppe Gold, Silber und/oder Platin ist
- Supramolekulares Nanosystem nach Anspruch 10, dadurch gekennzeichnet, daß der Halbleiter ausgewählt ist aus Cadmiumselenid und/oder Cadmiumsulfid.
- Supramolekulares Nanosystem nach Anspruch 10, dadurch gekennzeichnet, dass der Fluoreszenzmarker ein Fluoro- und/oder Chromophores ist.
- Supramolekulares Nanosystem nach Anspruch 10, dadurch gekennzeichnet, daß der Chelatbildner abgeleitet ist von Anthrocyanen, Polyoxycarbonsäuren, Polyaminen, Dimethylglyoxim, Ethylendiamintetraessigsäure und/oder Nitrilotriessigsäure.
- Supramolekulares Nanosystem nach einem der Ansprüche 1 - 14, dadurch gekennzeichnet, daß das Oligomer A mit dem Oligomer B nach Assoziation verknüpft ist.
- Bibliothek enthaltend mehrere verschiedene supramolekulare Nanosysteme gemäß einem der Ansprüche 1 - 15.
- Verfahren zur Herstellung eines supramolekularen Nanosystems gemäß einem der Ansprüche 1 - 15 oder einer Bibliothek gemäß Anspruch 16, dadurch kennzeichnet, daß das Oligomer A mit einem oder mehreren, gleichen oder verschiedenen Oligomeren B spezifisch gepaart wird.
- Verfahren nach Anspruch 17, dadurch gekennzeichnet, daß in einem weiteren Schritt das Oligomer A mit dem oder den Oligomeren B verknüpft wird.
- Verfahren zur strukturellen Änderung des supramolekularen Nanosystem gemäß einem der Ansprüche 1 - 15, dadurch gekennzeichnet, daß die Gleichgewichtsbedingungen durch Änderung der Konzentration an Oligomer B, der Salzkonzentration, des pH-Wertes, des Druckes und/oder der Temperatur geändert werden.
- Verfahren zur strukturellen Änderung einer Bibliothek enthaltend verschiedene supramolekulare Nanosysteme gemäß Anspruch 16, dadurch gekennzeichnet, daß die Gleichgewichtsbedingungen durch Änderung der Konzentration an Oligomer B, der Salzkonzentration, des pH-Wertes, des Druckes und/oder der Temperatur geändert werden.
- Verwendung eines supramolekularen Nanosystems gemäß einem der Ansprüche 1 - 15 als elektronischer Bauteil, Katalysator, Halbleiter, lichtchemische Einheit; biokompatibles Material bzw. Einheit oder funktionelle Mikroprothese.
- Verwendung einer Bibliothek enthaltend verschiedene supramolekulare Nanosystems gemäß Anspruch 16 als elektronisches Bauteil, Katalysator, Halbleiter, lichtchemische Einheit; biokompatibles Material bzw. Einheit oder funktionelle Mikroprothese.
- Verwendung einer Bibliothek gemäß Anspruch 16 zum Auffinden eines MetallKatalysators.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19651560 | 1996-12-11 | ||
DE19651560A DE19651560A1 (de) | 1996-12-11 | 1996-12-11 | Neue funktionelle supramolekulare Nanosysteme |
PCT/EP1997/006907 WO1998025943A1 (de) | 1996-12-11 | 1997-12-10 | Nicht-helikale supramolekulare nanosysteme |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0944641A1 EP0944641A1 (de) | 1999-09-29 |
EP0944641B1 true EP0944641B1 (de) | 2003-07-02 |
Family
ID=7814400
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97952911A Expired - Lifetime EP0944641B1 (de) | 1996-12-11 | 1997-12-10 | Nicht-helikale supramolekulare nanosysteme |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0944641B1 (de) |
JP (1) | JP2001509141A (de) |
KR (1) | KR20000057508A (de) |
AT (1) | ATE244260T1 (de) |
AU (1) | AU734804B2 (de) |
BR (1) | BR9714393A (de) |
CA (1) | CA2274671A1 (de) |
DE (2) | DE19651560A1 (de) |
WO (1) | WO1998025943A1 (de) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19741716A1 (de) * | 1997-09-22 | 1999-03-25 | Hoechst Ag | Adressierbares modulares Erkennungssystem, seine Herstellung und Verwendung |
DE19741715A1 (de) * | 1997-09-22 | 1999-03-25 | Hoechst Ag | Pentopyranosyl-Nucleosid, seine Herstellung und Verwendung |
DE19741739B4 (de) * | 1997-09-22 | 2006-04-27 | Nanogen Recognomics Gmbh | Supramolekulares Paarungssystem, dessen Herstellung und Verwendung |
DE19837387A1 (de) | 1998-08-18 | 2000-02-24 | Aventis Res & Tech Gmbh & Co | 3'-Desoxypentopyranosyl-Nucleinsäure, ihre Herstellung und Verwendung |
DE10010118A1 (de) * | 2000-03-03 | 2001-09-20 | Henkel Kgaa | Beschichtungssystem auf der Basis von Pyranosyl-Nukleinsäuren |
US6893822B2 (en) | 2001-07-19 | 2005-05-17 | Nanogen Recognomics Gmbh | Enzymatic modification of a nucleic acid-synthetic binding unit conjugate |
CA2463719A1 (en) | 2003-04-05 | 2004-10-05 | F. Hoffmann-La Roche Ag | Nucleotide analogs with six membered rings |
JP4849213B2 (ja) * | 2005-12-15 | 2012-01-11 | ライオン株式会社 | 育毛養毛剤 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5718915A (en) * | 1994-10-31 | 1998-02-17 | Burstein Laboratories, Inc. | Antiviral liposome having coupled target-binding moiety and hydrolytic enzyme |
-
1996
- 1996-12-11 DE DE19651560A patent/DE19651560A1/de not_active Withdrawn
-
1997
- 1997-12-10 EP EP97952911A patent/EP0944641B1/de not_active Expired - Lifetime
- 1997-12-10 KR KR1019990705196A patent/KR20000057508A/ko not_active Application Discontinuation
- 1997-12-10 BR BR9714393-6A patent/BR9714393A/pt not_active IP Right Cessation
- 1997-12-10 DE DE59710385T patent/DE59710385D1/de not_active Expired - Fee Related
- 1997-12-10 AU AU56612/98A patent/AU734804B2/en not_active Ceased
- 1997-12-10 AT AT97952911T patent/ATE244260T1/de not_active IP Right Cessation
- 1997-12-10 JP JP52622198A patent/JP2001509141A/ja active Pending
- 1997-12-10 WO PCT/EP1997/006907 patent/WO1998025943A1/de not_active Application Discontinuation
- 1997-12-10 CA CA002274671A patent/CA2274671A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE19651560A1 (de) | 1998-06-18 |
AU734804B2 (en) | 2001-06-21 |
AU5661298A (en) | 1998-07-03 |
EP0944641A1 (de) | 1999-09-29 |
ATE244260T1 (de) | 2003-07-15 |
KR20000057508A (ko) | 2000-09-15 |
JP2001509141A (ja) | 2001-07-10 |
CA2274671A1 (en) | 1998-06-18 |
DE59710385D1 (de) | 2003-08-07 |
WO1998025943A1 (de) | 1998-06-18 |
BR9714393A (pt) | 2000-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1017704B1 (de) | Verwendung eines konjugates enthaltend ein pentopyranosyl-nucleotid zur herstellung eines arrays | |
DE69433010T2 (de) | Verfahren zur darstellung von oligonukleotiden | |
DE60029042T2 (de) | Festphase Nukleinsäuremarkierung durch Transaminierung | |
EP1801114B1 (de) | Polynukleotid mit Phosphatmimetikum | |
DE19964220C2 (de) | Verfahren zur Herstellung einer modifizierten leitfähigen Oberfläche | |
EP1018007B1 (de) | Adressierbares modulares erkennungssystem, seine herstellung und verwendung | |
EP0944641B1 (de) | Nicht-helikale supramolekulare nanosysteme | |
EP0931038B1 (de) | Neue substanzbibliothek und damit hergestellte supramolekulare komplexe | |
DE69731112T2 (de) | Verfahren zur synthese von phosphorothioat-oligonukelotiden | |
DE3881691T2 (de) | Polydeoxyribonukleotide, pharmazeutische zusammensetzungen, verwendung und herstellung von polydeoxyribonukleotiden. | |
EP1070079B1 (de) | Verfahren zur herstellung von pentopyranosyl-nucleosiden | |
EP1049678B1 (de) | Cyclohexyl- und heterocyclyl-nukleosid derivate, die herstellung und verwendung dieser derivate, deren oligomere bzw. konjugate in paarungs- und/oder testsystemen | |
EP1105403B1 (de) | 3'-desoxypentopyranosyl-nucleinsäure und ihre herstellung | |
DE19921940C2 (de) | Verfahren zur elektrochemischen Detektion von Nukleinsäureoligomerhybriden | |
EP1034180A2 (de) | Linker-nucleosid, seine herstellung und verwendung | |
DE69001296T2 (de) | Verfahren zur reinigung von spezifischen oligonukleotiden. | |
DE10010118A1 (de) | Beschichtungssystem auf der Basis von Pyranosyl-Nukleinsäuren | |
WO1995016696A2 (de) | Modifizierte oligonukleotide, verfahren zu ihrer herstellung und verwendung als wirkstoffe |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19990610 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LI NL SE |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: NANOGEN RECOGNOMICS GMBH |
|
17Q | First examination report despatched |
Effective date: 20020404 |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE FR GB IT LI NL SE |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REF | Corresponds to: |
Ref document number: 59710385 Country of ref document: DE Date of ref document: 20030807 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) |
Effective date: 20031008 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20031126 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20031128 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20031201 Year of fee payment: 7 Ref country code: AT Payment date: 20031201 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20031202 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20031205 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20031209 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20040115 Year of fee payment: 7 |
|
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20040405 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20041210 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20041210 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20041211 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20041231 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20041231 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20041231 |
|
BERE | Be: lapsed |
Owner name: *NANOGEN RECOGNOMICS G.M.B.H. Effective date: 20041231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050701 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050701 |
|
EUG | Se: european patent has lapsed | ||
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20041210 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050831 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 20050701 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20051210 |
|
BERE | Be: lapsed |
Owner name: *NANOGEN RECOGNOMICS G.M.B.H. Effective date: 20041231 |